GPGraham Peigh

Graham Peigh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Graham Peigh has a total of 314 co-authors. Here are the top co-authors by number of shared publications:

  • Rod Passman

    Division of Cardiology, Feinberg School of Medicine, Northwestern University , 676 N St Claire, Suite 600, Chicago, IL 60611

    13 shared publications
  • Bradley P. Knight

    Feinberg School of Medicine, Division of Cardiology Northwestern University Chicago Illinois USA

    9 shared publications
  • Albert Lin

    Clinical Cardiac Electrophysiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    5 shared publications
  • Alexandru B. Chicos

    Division of Cardiology Northwestern University, Feinberg School of Medicine Chicago Illinois USA

    4 shared publications
  • Amar Trivedi

    Medical Center of the Rockies, Loveland, Colorado, USA

    4 shared publications
  • Bradley P. Knight

    Department of Medicine (Cardiology) Northwestern University Feinberg School of Medicine Chicago Illinois USA

    4 shared publications

Latest Publications

  • Open Access

    Safety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry

    by Rachel M Kaplan, Jeanne du Fay de Lavallaz, Christian-Hendrik Heeger, Hakan Oral, Mason Yoder, David Schaack, Julian K Chun, Boris Schmidt, Jeffrey Winterfield, William H Sauer, et al.

    Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.

  • Open Access

    Cardiac Implantable Electronic Device Infection: Nationwide Trends in Extraction Utilization and In‐Hospital Outcomes

    by Jay Manadan, Alexander Zheutlin, Bradley P. Knight, Albert C. Lin, Nishant Verma, Graham Peigh

    Introduction: Contemporary, real‐world adherence to guideline‐directed transvenous cardiac implantable electronic device (CIED) extraction for patients with CIED infections in the US remains incompletely characterized. As such, we sought to evaluate national trends in CIED extraction and identify factors associated with extraction and in‐hospital mortality. Methods: A retrospective analysis of adult hospitalizations with CIED infection using the National Inpatient Sample from 2016 to 2022 was performed. National trends in extraction, factors associated with extraction, and predictors of in‐hospital mortality were evaluated. Multivariable logistic regression and propensity score matching were used to estimate adjusted associations with mortality. Results: Among 47,835 adults hospitalized with a CIED infection, 10,905 (22.8%) underwent extraction. National extraction rates increased modestly from 16.2% in 2016 to 23.8% in 2022 ( p < 0.001) but remained low overall. Unadjusted in‐hospital mortality was lower among patients who underwent extraction compared with those who did not (2.8% vs. 4.4%; p = 0.001). After adjustment, extraction was independently associated with lower mortality (OR 0.59 [95% CI, 0.44–0.80]). Higher mortality was associated with increasing age, greater comorbidity burden, and markers of acute illness severity, including acute kidney injury, cardiogenic shock, and respiratory failure. Among patients who underwent extraction, markers of acute organ failure remained associated with adjusted in‐hospital mortality. Conclusions: In this contemporary, multi‐payor, national cohort of patients with CIED infections, CIED extraction was independently associated with lower in‐hospital mortality, but was significantly underutilized despite guideline recommendations. Mortality among those who underwent extraction was driven primarily by acute illness severity, emphasizing the need for early recognition and timely intervention. System‐level strategies to improve access to extraction may help align real‐world practice with guidelines.

  • Open Access

    Secondary Cardiac Lymphoma Causing High-Grade Heart Block

    by John Sollee, Graham Peigh, Kaustubha Patil, Albert Lin, Nausheen Akhter, Reem Karmali

  • Open Access

    Postoperative Atrial Arrhythmias After Lung Transplantation: A Single Center Analysis of Risk Factors, Management, and Outcomes

    by Daniel M. Chen, Ambalavanan Arunachalam, Graham Peigh, Bradley P. Knight, Chitaru Kurihara, Mrinalini Venkata Subramani, Catherine Myers, Alan Betensley, Krishnan Warrior, Bradford C. Bemiss, et al.

    Background: Postoperative atrial arrhythmia (POAA) is common after lung transplant, but data on its implications and management are limited. This study assessed POAA incidence and timing, its association with mortality and rehospitalizations, and outcomes related to postoperative beta‐blocker use. Methods: We retrospectively studied 233 adult lung transplant patients at Northwestern Memorial Hospital (2014–2024) without prior atrial arrhythmia. POAA, defined as atrial fibrillation or flutter, was confirmed by ECG or ambulatory monitoring. Multivariable logistic and Cox regression models evaluated predictors and outcomes, adjusting for covariates. Results: POAA occurred in 69/233 patients (29.6%) and was associated with higher mortality (HR3.09, 95%CI [1.57–6.08]). Among these, 18/69 (26.1%) developed POAA after the index hospitalization at median 216 days post‐transplant, also associated with higher mortality (HR4.37, 95%CI [1.90–10.06]). Additionally, 10/69 (14.5%) required emergency visits or hospitalization specifically for arrhythmia management, and 66.6% underwent additional rhythm control (2.9% cardioversion, 46.4% anti‐arrhythmic drug, 17.4% both). Postoperative beta‐blocker use was associated with 73% less POAA (HR0.27, 95%CI [0.09–0.80]). Conclusion: POAA was common and clinically significant after lung transplant, associated with substantially higher adjusted mortality even when occurring after index hospitalization. We report for the first time that POAA was frequently associated with emergency visits or rehospitalization for arrhythmia, highlighting its clinical burden well beyond the perioperative period. Postoperative beta‐blocker use was associated with markedly less POAA, a novel finding suggesting a potential prophylactic role. Overall, these findings challenge the traditional view of POAA as benign and highlight the need for tailored, evidence‐based guidelines in this high‐risk population.


  • Top Cited Papers

    Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients

    by Mohit K Turagam, Arash Aryana, John D Day, Srinivas R Dukkipati, Troy Hounshell, Devi Nair, Andrea Natale, Stanislav Weiner, Jim W Cheung, Larry Chinitz, et al.


  • Etripamil Nasal Spray to Keep the Doctor Away

    by Graham Peigh, Bradley P. Knight

  • Open Access

    Outcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement

    by Graham Peigh, Mohamed Al-Kazaz, Laura J. Davidson, Muhammed Gerçek, Max Potratz, S. Christopher Malaisrie, Rachel Finke, Zhiying Meng, Abigail S. Baldridge, Jing Gao, et al.


  • Open Access

    Implantable Defibrillators: Which Is the Best Device for Each Patient?

    by Graham Peigh, Bradley P. Knight

    The first viable alternative to surgical implantation of an epicardial defibrillator system for secondary prevention of sudden cardiac death (SCD) was a single chamber transvenous implantable cardioverter defibrillator (ICD). Thanks to technological advancements over the past 40 years, electrophysiologists now have several options when determining the optimal type of ICD to provide protection against SCD, including the number of leads implanted, whether a patient meets indications for cardiac resynchronization, and if the patient would benefit from an extravascular device. In this review, we will detail the breadth of options for commercially available ICD therapy to provide guidance on which device is best suited for specific patient populations.